An overview of the pathophysiology of neurodegenerative disorders

Alternative Therapies in Health and Medicine

Volumn 10, Issue 4, 2004, Pages

  Willner, Catherine ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; UBIDECARENONE; ANTIOXIDANT; FREE RADICAL; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROPROTECTIVE AGENT;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; APOPTOSIS; AUTONOMIC DYSFUNCTION; CHRONIC INFLAMMATION; CLINICAL FEATURE; CORTICOBASAL DEGENERATION; CREUTZFELDT JAKOB DISEASE; DEGENERATIVE DISEASE; EXTRAPYRAMIDAL SYNDROME; FRONTOTEMPORAL DEMENTIA; HUMAN; HUNTINGTON CHOREA; LEWY BODY; MULTIPLE SCLEROSIS; NEUROTOXICITY; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOPHYSIOLOGY; PROGRESSIVE SUPRANUCLEAR PALSY; REVIEW; RISK ASSESSMENT; SHY DRAGER SYNDROME; SPASTIC PARESIS; SPINAL MUSCULAR ATROPHY; SPINOCEREBELLAR DEGENERATION; SYSTEMATIC REVIEW; AGED; AGING; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG EFFECT; GENETICS; METABOLISM;

AGED; AGING; ANTIOXIDANTS; FREE RADICALS; HUMANS; MITOCHONDRIAL DISEASES; NEURODEGENERATIVE DISEASES; NEUROPROTECTIVE AGENTS; OXIDATIVE STRESS; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 4143126930     PISSN: 10786791     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (52)

1. Cummings J, Vinters H, Cole G, Khachaturian Z. Alzheimer's disease: etiologies, pathophysiology, cognitive reserve, and treatment opportunities. Neurology. 1998;51(suppl 1):S2-S17.
2. Bayer TA, Wirths O, Majteni K, et al. Key factors in Alzheimer's disease: beta-amyloid precursor protein processing, metabolism and intraneuronal transport. Brain Pathol. 2001;11:1-11.
3. Goedert M. Introduction to the tauopathies. In: Diceson D, et. Neurodegeneration: the molecular pathology of dementia and movement disorders. Basel: ISN Neuropath Press. 2003;82-85.
4. Aarsland D, Ballard C, Olarsen JP, McKeith I. A comparative study of psychiatric symptoms in dementia with Lewy bodies and Parkinson's disease with and without dementia. Internat J Geriatr Psychiatry. 2001;16:528-536.
5. Hirsch ED, Brandel JP, Galle P, et al. Iron and aluminum increase in the substantia nigra of patients with Parkinson's disease: an x-ray microanalysis. J Neurochem. 1991;56:446-451.
6. Bowen J, Teri L, Kukull W, et al. Progression to dementia in patients with isolated memory loss. Lancet. 1997;349:763-765.
7. Warner TT, Schapira AH. Genetic and environmental factors in the cause of Parkinson's disease. Ann Neural. 2003;53(suppl 3):S16-S25.
8. Chapman J, Korczyn AD, Karussis DM, Michaelsonn DM. The effects of APOE genotype on age at onset and progression of neurodegenerative diseases. Neurology. 2001;57:1482-1485.
9. Shapira, AHV, Cooper JM, Dexter D, Clarck JB, Jenner P, Marsden CD. Mitochondrial complex I deficiency in Parkinson's disease. J Neurochem. 1990;54:823-827.
10. Parker WD, Boyson SJ, Parks JK. Abnormalities of the electron transport chain in idiopathic Parkinson's disease. Ann Neurol. 1989;26:719-723.
11. Albers, DS and Beal MF. Mitochondrial dysfunction and oxidative stress in aging and neurodegenerative disease. J Neurol Transm. Supple. 59:133-154, 2000.
12. Langsten JW, Ballard P, Tetrud JW, Irwin I. Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science. 1983;219:979-980.
13. Przedborski S, Jackson-Lewis V. Mechanisms of MPTP toxicity. Mov Disord. 1998:13(suppl 1):S35-S38.
14. Virmani MA, Biselli R, Spadoni A, et al. Protective actions of L-carnitine and acetyl-L-carnitine on the neurotoxicity evoked by mitochondrial uncoupling or inhibitors. Pharmacol Res. 1995;32:383-389.
15. Brooks JO III, Yesavage JA, Cara A, Bravi D. Acetyl L carnitine slows decline in younger patients with Alzheimer's disease. Neurobiol Aging. 1995;16:1-4.
16. Thai LJ, Cara A, Clarke, WR, et al. A 1-year multicenter placebo-controlled study of acetyl-L-carnitine in patients with Alzheimer's disease. Neurology. 1996;47:705-711.
17. Matsubara T, Azuma T, Yoshida S, Yamagami T. Serum coenzyme Q10 level in Parkinson syndrome. In: Folkers K, Littarru GP, Yamagami T, eds. Biomedical and Clinical Aspects of Coenzyme Q. New York, NY: Elsevier Science Publishers: 1991:159-166.
18. Shults CW, Oakes D, Kieburtz K, et al. Effects of Coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch Neurol. 2002;59:1541-1550.
19. Mecocci P, MacGarvey U, Kaufman AAE, et al. Oxidative damage to mitochondrial DNA shows marked age-dependent increases in human brain. Ann Neurol. 1993;34:609-616.
20. Wallace DC, Je JH, Neckelmann SN, et al. Sequence analysis of cDNAs for the human and bovine ATP synthase beta unit: mitochondrial DNA genes sustain seventeen times more mutations. Curr Genet. 1987;12:81-90.
21. Nekhaeva E, Bodyak Y, Kraytsberg SB, et al. Clonally expanded mtDNA point mutations are abundant in individual cells of human tissues. Proc Natl Acad Sci. 2002 Apr 16;99:5521-6.
22. Jellinger KA. Cell death mechanisms in Parkinson's disease. J Neurol Transm. 2000;107:1-29.
23. Zhang SM, Hernan MA, Chen H, et al. Intakes of vitamins E and C, carotenoids, vitamin supplements and PD risk. Neurology. 2002;59:1161-1169.
24. Nelson JL, Bernstein PS, Schmidt MC, Von Tress MS, Askew EW. Dietary modification and moderate antioxidant supplementation differentially affect serum carotenoids, antioxidant levels and markers of oxidative stress in older humans. J Nutr. 2003;133:3117-3123.
25. Prior RL. Fruits and vegetables in the prevention of cellular oxidative damage. Am J Clin Nutr. 2003:78(suppl):570S-578S.
26. Dragland S, Senoo H, Wake K, Holte K, Blomhoff R. Several culinary and medicinal herbs are important sources of dietary antioxidants. J Nutr. 2003;133:1286-1290.
27. Packer L, Tritschler HJ, Essel K. Neuroprotection by the metabolic antioxidant alpha-lipoic acid. Free Radic Biol Med. 1997;22:359-378.
28. Wu G, Fang Y-Z, Yang S, Lupton JR, Turner ND. Glutathione metabolism and its implications for health. J Nutr. 2004;134:489-492.
29. Mann CLA, Davies MB, Boggild MD, et al. Glutathione S-transferase polymorphisms in MS: their relationship to disability. Neurology. 2000;54:552-557.
30. Migliore L, et al. Oxidative damage and cytogenetic analysis in leukocytes of Parkinson's disease patients. Neurology. 2002;58:1809-1815.
31. Pitchumoni SS, Doraiswamy PM. Current status of antioxidant therapy for Alzheimer's disease. J Am Geriatr Soc. 1998;46:1566-1572.
32. Halliwell B. Why and how should we measure oxidative DNA damage in nutritional studies? How far have we come? Am J Clin Nutr. 2000;72:1082-1087.
33. Montine TJ, Markesbery WR, Zackert W, et al. The magnitude of brain lipid peroxidation correlates with the extent of degeneration but not with the density of neuritic plaques or fibrillary tangles or the APOE genotype in Alzheimer's disease patients. Am J Pathol. 1999;155:863-868.
34. Rajendra W, Armugam A, Jeyaseelan K. Neuroprotection and peptide toxins. Brain Res Rev. 2004;45:125-141.
35. Tayor CP, Meldrum BS. Na channels as targets for neuroprotective drugs. Trends Pharmacol Sci. 1995;16:309-316.
36. Peters A, Palay SL, Webster HDF. The Fine Structure of the Nervous System: The Neurons and Supporting Cells. Philadelphia: WB Saunders, 1976.
37. Travis J. Glia: the brain's other cells. Science. 1994;266:970-972.
38. Wood P. Microglia: roles of microglia in chronic neurodegenerative diseases. In: Wood, P, ed,. Neuroinflammation: Mechanisms and Management. 2nd ed. Humana Press, 2003.
39. Itagaki S, McGeer PL, Akiyama H, et al. Relationship of microglia and astrocytes to amyloid deposits of Alzheimer disease. J Neuroimmunol. 1989;24:173-182.
40. Wegiel J, Wang KC, Tarnawski M, Lach B. Microglia cells are the driving force in fibrillary plaque formation, whereas astrocytes are a leading factor in plaque degradation. Acta Neuropathol. 2000;100:356-364.
41. McGeer PL, Rogers J. Anti-inflammatory agents as a therapeutic approach to Alzheimer's disease. Neurology. 1992;42:447-449.
42. Hoozemans JJ, Veerhuis R, Rozemuller AJ, Eikelenboom P. Non-steroidal anti-inflammatory drugs and cyclooxygenase in Alzheimer's disease. Curr Drug Targets. 2003;4:461-8.
43. Cagnin A, Brooks DJ, Kennedy AM, et al. In-vivo measurement of activated microglia in dementia. Lancet. 2001;358:461-467.
44. Hess DC, Demechuk AM, Brass LM, Yatsu FM. HMG-CoA reductase inhibitors (statins): a promising approach to stroke prevention. Neurology. 2000;54:790-796.
45. VITAL Trial Collaborative Group. Effect of vitamins and aspirin on markers of platelet activation, oxidative stress and homocysteine in people at high risk of dementia. Journal of Internal Medicine. 2003;254:67.
46. LeBlanc, Andréa C. Apoptosis Techniques and Protocols. Second Edition. McGill University, 2002.
47. Watters D, Lavin M. Signalling Pathways in Apoptosis. T&F STM, 1999.
48. Jellinger KA. Apoptosis vs. nonapoptotic mechanisms in neurodegeneration. In: Wood, P, ed. Neuroinflammation: Mechanisms and Management. Second ed. Humana Press, 2003, 30.
49. Shapira, AHV, Olanow, CW. Neuroprotection in Parkinson disease: mysteries, myths, and misconceptions. JAMA. 2004;291:358-364.
50. Schapira, AHV. Neuroprotection and dopamine agonists. Neurology. 2002;58:9S-S18.
51. Bjorklund A, Dunnett SB, Brundin P, et al. Neural transplantation for the treatment of Parkinson's disease. Lancet Neurol. 2003;2:437-45.
52. Marsden CD, Olanow CW. The causes of Parkinson's disease are being unraveled and rational neuroprotective therapy is close to reality. Ann Neurol. 1998;44(suppl 1):S189-S196.